Immunomedix (US) presents early LeukoScan data:
This article was originally published in Clinica
Executive Summary
Immunomedix (US) says its infectious disease diagnostic, LeukoScan, is at least as good as indium-111 white blood cell imaging, but much easier to perform. The data, presented on June 12th at the Society of Nuclear Medicine's annual meeting (Pines Bay, Florida), come from one of the 14 Phase III trial sites. Immunomedix is currently assessing clinical data on bone infection and diabetic foot ulcers. Phase IIIs on prosthesis infection and appendicitis are continuing.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.